linjc16/ctgov huggingface dataset:
Efficacy of Hydrotherapy in Peripheral Neuropathy

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to evaluate the efficacy of hydrotherapy on pain and balance in patients affected by neuropathy.

Conditions
-----------------
Peripheral Neuropathy

Intervention / Treatment
-----------------
* Other: hydrotherapy
* Other: on land therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients affected by peripherical neuropathy able to walk Exclusion Criteria: pain of water medical contraindications at treatment in heated swimming pool

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: hydrotherapy<br>patients receive daily conventional physiotherapy and three 30- minutes sessions of in- water exercises per week, for four weeks | Other: hydrotherapy<br>* 30 minutes sessions of physiotherapy exercises in heated pool (32°C), three times per week for four weeks<br>|
| Active Comparator: controls<br>patients receive daily conventional physiotherapy and three 30- minutes sessions of on- land exercises per week, for four weeks | Other: on land therapy<br>* 30 minutes sessions of physiotherapy exercises on land, three times per week for four weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| balance change assessed using Berg Balance Scale |  | 0 and 4 weeks | 
| disability change assessed using Functional Independence Measure scale |  | 0 and 4 weeks | 
| gait change assessed using Dynamic Gait Index scale |  | 0 and 4 weeks | 
| gait change assessed using Functional Ambulation Classification scale |  | 0 and 4 weeks | 
| pain change assessed using Overall Neuropathy Limitation Scale |  | 0 and 4 weeks | 
| disability change assessed using Neuropathy Pain Scale |  | 0 and 4 weeks |
The Effect of Laser-assisted Zona Thinning on the Implantation Rate in the Women of Advanced Age

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether laser-assisted zona thinning improve the implantation rate of the women of advanced age in the first IVF/ICSI cycles

Detailed Description
-----------------
Registry procedures： It's required to sign an informed consent form prior to the recruitment of all patients. Data collection and entry need double check and supervision. The outcome measures: the implantation rate per embryo transfer miscarriage live birth

Official Title
-----------------
Center of Assisted Reproductive Technology

Conditions
-----------------
Female Urogenital Diseases

Intervention / Treatment
-----------------
* Device: ZILOS-TK IVOS Analyzer


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age: 35y ≤age≤46y Basal FSH value: FSH≤10IU/L Day-3 embryos transferred in the fresh IVF/ICSI cycles the number of embryos available to be transferred on Day-3: ≥one embryo Exclusion Criteria: cycles with thawed/warmed embryos biopsied for PGD/PGS. cycles with oocyte donation transfer. the maximum number of previous unsuccessful IVF attempts: ≥ 3 cycles(transfer cycles) any cycles with the risk of OHSS, fluid in the uterine cavity, abnormal endometrium, uterine abnormalities,pelvic inflammation, and other acute maternal problems. One or both spouses have an abnormal karyotype (including polymorphism)

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 46 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Assisted hatching group (AH group)<br>The subjects are going to participate the treatment of assisted hatching in vitro fertilization by Zona Infrared Laser Optical System (ZILOS-TK IVOS Analyzer,Hamilton Thorne Biosciences,USA). | Device: ZILOS-TK IVOS Analyzer<br>* The subjects are going to participate the treatment of assisted hatching in vitro fertilization by Zona Infrared Laser Optical System (ZILOS-TK,Hamilton Thorne Biosciences,USA)<br>|
| No Intervention: Control group<br>The subjects are going to undergo the same procedure except for the treatment of assisted hatching. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The implantation rate | the implantation rate per embryo in first fresh embryos transfer cycles | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The miscarriage |  | 24 weeks |
Study to Find the Percentage of Cases Retaining COVID-19 IgG Antibodies 45-65 After They Have Tested Positive

Study Overview
=================
Brief Summary
-----------------
As a serosurveillance measure asymptomatic employees of an industrial workforce Jamshedpur (India) were tested for COVID-19 IgG antibodies. Of the tested employees who were positive for COVID-19 IgG antibodies the study aimed to find the percentage of cases who retained their COVID-19 IgG antibodies 45-65 days after initially testing positive.

Detailed Description
-----------------
As a serosurveillance measure, 3296 asymptomatic employees of an industrial workforce Jamshedpur (India) were tested for COVID-19 IgG antibodies specific for the spike subunit antigen by the ErbaLisa COVID-19, Erba Corporate Services (United Kingdom) between 28th June and 15th July 2020. The cases who tested positive for COVID-19 IgG antibodies were repeat tested for the presence of COVID-19 IgG at 45-65 days after initially testing positive. This was done with the aim of finding out the percentage of cases retaining their IgG antibodies at 45-65 days of initially testing positive.

Official Title
-----------------
Study to Find the Percentage of Cases Retaining COVID-19 IgG Antibodies 45-65 After They Have Tested Positive

Conditions
-----------------
Covid19

Intervention / Treatment
-----------------
* Diagnostic Test: Repeat SARS-CoV-2 IgG antibodies at 45-65 days


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: SARS-CoV-2 IgG antibody positive between 28th June and 15th July 2020 Exclusion Criteria: SARS-CoV-2 IgG antibody negative between 28th June and 15th July 2020

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| SARS-CoV-2 IgG antibody positive between 28th June to 15th July 2020<br>As a serosurveillance measure, 3296 asymptomatic employees of an industrial workforce Jamshedpur (India) were tested for SARS-CoV-2 IgG antibodies specific for the spike subunit antigen by the ErbaLisa COVID-19, Erba Corporate Services (United Kingdom) between 28th June and 15th July 2020. All those who initially tested SARS-CoV-2 IgG antibody positive were retested at 45-65 days | Diagnostic Test: Repeat SARS-CoV-2 IgG antibodies at 45-65 days<br>* All cases who initially tested positive for SARS-CoV-2 IgG antibodies would undergo a repeat test at 45-65 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of cases retaining SARS-CoV-2 IgG antibodies at 45-65 days | Percentage of cases retaining SARS-CoV-2 IgG antibodies at 45-65 days | 45-65 days |
Quantitative Evaluation of the Progression of Liver Disease, Using ShearWaveTM

Study Overview
=================
Brief Summary
-----------------
Liver biopsy for the assessment of fibrosis has multiple limitations. Liver ShearWaveTM Elastography may provide a non-invasive, fast, and reproducible alternative for the quantitative assessment of liver fibrosis.

Detailed Description
-----------------
To obtain a quantitative evaluation of the progression of liver disease, using ShearWaveTM Elastography measurements obtained with the Supersonic Imagine Aixplorer ultrasound machine. To compare the glomerular filtration rate and the quantitative evaluation of the progression of renal disease, using ShearWaveTM Elastography measurements obtained with the Supersonic Imagine Aixplorer ultrasound machine in post-liver transplantation patients.

Official Title
-----------------
Quantitative Evaluation of Liver Disease With Liver and Kidney Elastography Using the Supersonic Imagine Aixplorer ShearWaveTM Elastography Ultrasound Machine

Conditions
-----------------
Liver Disease, Heart Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males and Females over the age of 18 Patients of Liver Consultant's of Texas Dallas office, with chronic liver disease or liver transplant patient seen in Liver Transplant Clinic Patients diagnosed with heart failure Exclusion Criteria: - Any person unable to provide an informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Shearwave Elastography Ultrasound | Patients will have a scan performed at their regularly scheduled clinic visits. | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
heart failure, liver failure, post liver transplant
Phase II Pilot Study of Aminoimidazole Carboxamide Riboside (AICAR), a Precursor of Purine Synthesis, for Lesch-Nyhan Disease

Study Overview
=================
Brief Summary
-----------------
OBJECTIVES: I. Determine the effects of aminoimidazole carboxamide riboside (AICAR) on hematologic manifestations of Lesch-Nyhan disease. II. Assess the behavioral and neurological benefits of AICAR in patients with Lesch-Nyhan disease. III. Examine the effect of AICAR on purine production.

Detailed Description
-----------------
PROTOCOL OUTLINE: After a 3-day baseline, patients are treated with aminoimidazole carboxamide riboside (AICAR) by continuous infusion for 12 days. Concurrent allopurinol and folate are allowed.

Conditions
-----------------
Lesch-Nyhan Syndrome

Intervention / Treatment
-----------------
* Drug: aminomidazole carboxamide riboside


Participation Criteria
=================
Eligibility Criteria
-----------------
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Men with Lesch-Nyhan syndrome Moderate erythrocyte macrocytosis No active urinary tract disease or impaired renal function

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: aminomidazole carboxamide riboside|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lesch-Nyhan syndrome, inborn errors of metabolism, neurologic and psychiatric disorders, rare disease
Implementation of the S'TIM Serious-Game for Rehabilitation of Dysexecutive Disorders (S'TIM)

Study Overview
=================
Brief Summary
-----------------
This study proposes to improve the management of dysexecutive syndrome by a serious game (SG) in addition to the usual management including work in occupational therapy and neuropsychology.

Official Title
-----------------
Implementation of the S'TIM Serious-Game for Rehabilitation of Dysexecutive Disorders

Conditions
-----------------
Dysexecutive Syndrome, Serious Game

Intervention / Treatment
-----------------
* Device: Serious Game S'TIM


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: French-speaking male or female patient at least 18 years old Patient suffering from recent disorders (less than 6 months) of executive functions Patient with sufficient mobility of the upper limb (mobility of the dominant upper limb greater than 70 °) to interact with the device. Patient affiliated or beneficiary of a social security scheme Patient having signed the free and informed consent. Exclusion Criteria: Patient participating in another clinical study Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision, Pregnant or breastfeeding woman, Patient hospitalized without consent. Patient with unstable psychiatric disorders Patient with comprehension disorders (alexia, visual agnosia, illiteracy, not understanding the language, etc.) Patient with executive function disorders greater than 6 months Negligent hemi patient Patient not familiar with the French language Patient with major neuro-visual disorders.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patients with Serious Game<br> | Device: Serious Game S'TIM<br>* Video Game S'tim : the patient is inside a bedroom and he has to find a friend outside. this game will study the orientation, the memory of the patient<br>|
| No Intervention: Patients without Serious Game<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The effect of using the serious-game S'TIM in terms of cognition | TAP sub-test ERFC : overall cognitive functions BREF : presence or absence of a cognitive and / or behavioral dysexecutive syndrome | 6 weeks | 
| The effect of using the serious-game S'TIM at 6 weeks in terms of metacognition with the BRIEF-A | Behaviour Rating Inventory of Executive Function, Adult | 6 weeks | 
| The effect of using the serious-game S'TIM at 6 weeks in terms of behavior with BRIEF-A | Behaviour Rating Inventory of Executive Function, Adult | 6 weeks |
Ranibizumab Treatment for Retinal Vein Occlusion

Study Overview
=================
Brief Summary
-----------------
In retinal vein occlusion, predictive factors for visual outcome after ranibizumab treatment have not been evaluated comprehensively. Therefore, we have planned to analyze predictors for visual outcome from a viewpoint of electrophysiology and biomarkers besides morphological features by SD-OCT.

Official Title
-----------------
Predictive Factors of 2-year Visual Outcome in Retinal Vein Occlusion Following Intravitreal Ranibizumab Treatment

Conditions
-----------------
Macular Edema Due to BRVO/CRVO

Intervention / Treatment
-----------------
* Drug: Ranibizumab, 0.5mg, Intravitreal


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed informed consent form Male or female of aged 18 years or older Macula edema secondary to BRVO/CRVO Decrease of VA due to macular edema Exclusion Criteria: Prior episode of RVO Previous treatment with anti-VEGF drugs or corticosteroid or grid laser photocoagulation (study eye) Ocular disorders in the study eye that may confound interpretation of study results History of vitrectomy surgery, submacular surgery, or other surgical intervention for RVO The pregnant or lactating woman

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Intravitreal Lucentis 0.5mg<br>One arm | Drug: Ranibizumab, 0.5mg, Intravitreal<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean foveal thickness measured by SD-OCT |  | 2 years |
Artificial Root-End Barriers

Study Overview
=================
Brief Summary
-----------------
This study retrospectively looks to determine the clinical success of ProRoot MTA used as an artificial apical barrier in teeth with immature apices.

Detailed Description
-----------------
The normal development and maturation of a root depends on a vital, healthy pulp. If the pulp becomes necrotic in a tooth with an immature apex, endodontic treatment can be performed using an artificial barrier technique. Mineral trioxide aggregate (MTA) has become the material of choice to accomplish this procedure, however, few studies have evaluated its clinical success. The purpose of this retrospective study was to determine the clinical success of ProRoot MTA used as an artificial apical barrier. Twenty patients were included in this study. After approximately one week of Ca(OH)2 treatment, each patient had MTA placed as an apical barrier in a tooth with a single canal and open apex followed by placement of a final restoration. Patients were recalled and evaluated for clinical signs and symptoms and osseous healing. Immediate post-treatment and recall radiographs were evaluated by two endodontists calibrated for use of the Periapical Index (PAI).

Official Title
-----------------
Clinical Success of Artificial Root-End Barriers With Mineral Trioxide Aggregate in Teeth With Immature Apices

Conditions
-----------------
Dental Cements, Tooth Abnormalities

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: a tooth with a single canal and presence of an open apex by radiograph Ca(OH)2 treatment for at least one week prior to obturation use of MTA to produce an artificial apical barrier placement of a final restoration radiographs codumenting pretreatment and immedicate post-treatment conditionof the tooth patients ages 5-40 years old Exclusion Criteria: patients younger than 5 and greater than 40 years old patients unable to be contacted for recall during the study patients with a medical condition whose health would be jeopardized by participation in the study

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group one<br>Subjects are drawn from a search of all patients treated with MTA between ages 5-40 | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Mineral trioxide aggregate
A Study of the Safety and Pharmacokinetics of PRO283698 in Patients With Rheumatoid Arthritis

Study Overview
=================
Brief Summary
-----------------
This is a Phase I multicenter study that will be conducted in the United States and Europe.

Official Title
-----------------
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Pharmacokinetics of PRO283698 in Patients With Rheumatoid Arthritis

Conditions
-----------------
Rheumatoid Arthritis

Intervention / Treatment
-----------------
* Drug: placebo
* Drug: PRO283698


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: RA diagnosed according to the American College of Rheumatology (ACR) Exclusion Criteria: Female patients who are pregnant, plan to become pregnant during the study, or are breastfeeding Clinically significant abnormal ECG History of anaphylactic reactions Positive hepatitis C antibody or hepatitis B surface antigen Positive serology for human immunodeficiency virus (HIV) by quantitative polymerase chain reaction A history of an autoimmune disease other than RA (other than secondary Sjogren syndrome) Significant systemic involvement of RA, including vasculitis, pulmonary fibrosis, or Felty syndrome Malignancy, or prior malignancy, other than non-melanoma skin cancer, or cervical carcinoma in situ that has been resected Recent administration of a live, attenuated vaccine, or anticipation that such a live attenuated vaccine will be required during the study or within 60 days after the last dose Concomitant therapy with a biologic agent Recent exposure to any investigational agent Any current or recent signs or symptoms of infection requiring parenteral antibiotic administration Hospitalization for a clinically relevant event within the 4 weeks prior to screening

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: PRO283698<br>* Intravenous and subcutaneous ascending dose<br>|
| Placebo Comparator: 2<br> | Drug: placebo<br>* Intravenous and subcutaneous ascending dose<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and tolerability of PRO283698 assessed through the incidence of adverse events |  | Through study completion or early study discontinuation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetic parameters |  | Following study drug administration | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
RA